Macrolide treatment failure in community-acquired pneumonia and associated clinical consequences

被引：0
|
作者：
Wu, JH [1 ]
McGowan, JE [1 ]
Howard, MH [1 ]
Frau, LM [1 ]
Dai, WS [1 ]
机构：
[1] Aventis Pharmaceut, Bridgewater, NJ USA
来源：
CHEST | 2004年 / 126卷 / 04期
关键词：
D O I：
10.1378/chest.126.1.2
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：736S / 737S
页数：2
相关论文
共 50 条
  • [1] Implications for macrolide treatment in community-acquired pneumonia
    Mundy, LM
    Oldach, D
    Auwaerter, PG
    Gaydos, CA
    Moore, RD
    Bartlett, JG
    Quinn, TC
    CHEST, 1998, 113 (05) : 1201 - 1206
  • [2] Treatment failure in community-acquired pneumonia
    Menendez, Rosario
    Torres, Antoni
    CHEST, 2007, 132 (04) : 1348 - 1355
  • [3] Treatment Failure and Clinical Stability in Severe Community-Acquired Pneumonia
    Mendez, Raul
    Gonzalez-Jimenez, Paula
    Mengot, Noe
    Menendez, Rosario
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (02) : 225 - 236
  • [4] Addition of Macrolide Antibiotics for Hospital Treatment of Community-Acquired Pneumonia
    Wei, Jia
    Walker, A. Sarah
    Eyre, David W.
    JOURNAL OF INFECTIOUS DISEASES, 2025,
  • [5] Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia
    Arnold, Forest W.
    Lopardo, Gustavo
    Wiemken, Timothy L.
    Kelley, Robert
    Peyrani, Paula
    Mattingly, William A.
    Feldman, Charles
    Gnoni, Martin
    Maurici, Rosemeri
    Ramirez, Julio A.
    Arnold, Forest
    Peyrani, Paula
    Ramirez, Julio
    Ayesu, Kwabena
    File, Thomas, Jr.
    Burdette, Steven
    Blatt, Stephen
    Restrepo, Marcos
    Bordon, Jose
    Gross, Peter
    Musher, Daniel
    Marrie, Thomas
    Weiss, Karl
    Roig, Jorge
    Lode, Harmut
    Welte, Tobias
    Aliberti, Stephano
    Blasi, Francesco
    Cosentini, Roberto
    Legnani, Delfino
    Franzetti, Fabio
    Montano, Nicola
    Cervi, Giulia
    Rossi, Paolo
    Voza, Antonio
    Ostrowsky, Belinda
    Pesci, Alberto
    Nava, Stefano
    Viale, Pierluigi
    Galavatti, Vanni
    Patricia, Aruj
    Dimas, Carlos
    Piro, Roberto
    Viscoli, Claudio
    Torres, Antoni
    Valenti, Vincenzo
    Portela Ojales, Daniel
    Bodi, Maria
    Porras, Jose
    Rello, Jordi
    RESPIRATORY MEDICINE, 2018, 140 : 115 - 121
  • [6] Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez, F
    Mensa, J
    Martínez, JA
    García, E
    Marco, F
    González, J
    Marcos, MA
    Soriano, A
    Torres, A
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) : 1239 - 1245
  • [7] Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Halpern, MT
    Cifaldi, MA
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) : 144 - 145
  • [8] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
    Endimiani, A
    Brigante, G
    Bettaccini, AA
    Luzzaro, F
    Grossi, P
    Toniolo, AQ
    BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [9] Early and Late Treatment Failure in Community-Acquired Pneumonia
    Garcia-Vidal, Carolina
    Carratala, Jordi
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 30 (02) : 154 - 160
  • [10] Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
    Andrea Endimiani
    Gioconda Brigante
    Alessia A Bettaccini
    Francesco Luzzaro
    Paolo Grossi
    Antonio Q Toniolo
    BMC Infectious Diseases, 5
12345